Table 2 Overview of patients who, according to our criteria, are considered to have OMD
From: Proposal for a definition of "Oligometastatic disease in pancreatic cancer"
# | Study participation | Overall survival [mo] | Primary tumor: Max. diameter [cm] | Primary tumor: Location | M: Liver count | Liver max metastasis [cm] | M: Liver location | M: Lung count | M: Lung max. Diameter [cm] | Chemo: First line | Bilirubin level [mg/dL] BL | LDH [U/L] BL | CRP [mg/L] BL | CA 19–9 [U/mL] BL | CEA [μg/L] BL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | No | 16.1 | 4.1 | Tail | 4 | 4.1 | Right lobe | – | Gemcitabine + nab-Paclitacxel | 0.3 | 208 | 45.9 | 6 | 2.8 | |
2 | ACCEPT | 16.0 | 5.0 | Tail | 3 | 6.3 | Both lobes | – | Gemcitabine + Afatinib | 0.3 | 393 | 63.1 | 22 | 80.2 | |
3 | No | 22.9 | n.a. | Tail | 2 | 4.4 | Both lobes | – | Gemcitabine + Erlotinib | 1.2 | 209 | 64.9 | 33 | 1.7 | |
4 | No | 27.7 | 2.4 | Head | 4 | 1.1 | Both lobes | – | Gemcitabine + nab-Paclitacxel | 1.7 | 246 | 32.5 | 885 | 7.7 | |
5 | RESOLVE (PCYC-1137-CA) | 14.0 | 2.9 | Tail | 4 | 1.4 | Right lobe | – | Ibrutinib/Placebo + nab-Paclitacxel + Gemcitabine | 0.7 | 180 | 6.0 | 229 | 1.6 | |
6 | No | 19.4 | 4.6 | Body | 2 | 0.9 | Left lobe | – | Gemcitabine + Erlotinib | 0.2 | 198 | 4.3 | 154 | 3.8 | |
7 | No | 4.8 | 3.6 | Head | 3 | 0.9 | Both lobes | – | Gemcitabine | 0.3 | 179 | 23.1 | 2 | 3.2 | |
8 | No | 27.2 | 4.2 | Body | 4 | 1.6 | Right lobe | – | Gemcitabine | 0.3 | 230 | 5.0 | 36 | 7.6 | |
9 | No | 28.6 | 9.0 | Body | – | – | – | 4 | 4.5 | Capecitabine | 0.2 | 276 | 9.2 | 790 | 1.8 |
10 | No | 19.5 | 4.8 | Body | – | – | – | 2 | 0.5 | Gemcitabine | 0.5 | 256 | 3.0 | 148 | 2.6 |